SCHEMBL14728115

SCHEMBL14728115

CCn1c2ccccc2c2cc3c4ccc(N(c5ccc6ccccc6c5)c5cccc6ccccc56)cc4c4ccccc4c3cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
KDM4E B2RXH2 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HTT P42858 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
MAPK1 P28482 2/20 0.40
HBB P68871 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PER2 O15055 2/20 0.39
CRY1 Q16526 2/20 0.39
CRY2 Q49AN0 2/20 0.39
KDM1A O60341 1/20 0.38
NPY5R Q15761 2/20 0.37
LMNA P02545 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728109 0.93 KDM1A (0.41) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL14728111 0.93 KDM4E (0.43) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL14728123 0.91 KDM4E (0.45) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL14728120 0.90 NPY5R (0.41) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL14728121 0.86 NPY5R (0.43) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL14728119 0.84 MAPT (0.34) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL6604512 0.84 KDM4E (0.48) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL14728185 0.81 KDM4E (0.40) KDM4EPER2CRY1CRY2
SCHEMBL14728107 0.81 KDM4E (0.49) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL22303004 0.81 HPRT1 (0.44) ALDH1A1HPGDHSD17B10TDP1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9017829-B2 Phenanthrocarbazole compound, and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2015-04-28 US disclosed
US-9017829-B2 Phenanthrocarbazole compound, and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2015-04-28 US disclosed
US-20130048975-A1 PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2013-02-28 US disclosed
US-20130048975-A1 PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130048975-A1 PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME PPOX, ORC3, CACNA2D3 MAPT 589/4885KDM4E 1626/4885MEN1 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.